Alnylam Pharmaceuticals ALNY Other license programs — Total revenues

Other product segments

Similar metrics at other companies

BCRXLicense and other revenues — Total revenues

$5.01M+187%

SUPNRoyalty, licensing, and other revenues — Total revenues

$29.31M+274%

NVAXLicensing, royalties, and other — Total Revenue

$97.31M+116%

ARDXLicensing revenue — Total revenues

$51K-99.0%

NTRALicensing and other revenues — Total revenues

$2.78M+54.7%

RCUSLicense and development services — Total revenues

$12M-40.0%

Questions, answered.

What is Alnylam Pharmaceuticals's other license programs — total revenues?

Alnylam Pharmaceuticals (ALNY) reported other license programs — total revenues of $5.82M in Q2 2026.

How has Alnylam Pharmaceuticals's other license programs — total revenues changed year-over-year?

Alnylam Pharmaceuticals's other license programs — total revenues decreased by 70.3% year-over-year, from $19.59M to $5.82M.

What is the long-term trend for Alnylam Pharmaceuticals's other license programs — total revenues?

Over 2 years (2023 to 2025), Alnylam Pharmaceuticals's other license programs — total revenues has grown at a 34.1% compound annual growth rate (CAGR), from $27.97M to $50.27M.

What does other license programs — total revenues mean?

This metric represents the total revenue generated from licensing agreements, intellectual property partnerships, and collaborative research arrangements outside of the company's primary commercialized therapeutic franchises. It reflects the monetization of the company's proprietary technology platform and non-core pipeline assets through third-party partnerships. Growth in this segment indicates successful commercialization of the company's underlying research capabilities and the ability to extract value from secondary clinical programs.